Next Article in Journal
Tacrolimus Induced Organ Failure: Reversal by Activation of the Cytochrome P450-3a System
Previous Article in Journal
Holmium Laser Enucleation of the Prostate Efficiency by Prostate Gland Size: Is There a Sweet Spot?
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:

Urological Manifestations of the Systemic Vasculitides—A Scoping Review

University Center of Excellence in Urology, Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland
Department of Otolaryngology, Head and Neck Surgery, Wroclaw Medical University, 50-556 Wroclaw, Poland
Authors to whom correspondence should be addressed.
Uro 2021, 1(4), 209-221;
Submission received: 26 September 2021 / Revised: 2 November 2021 / Accepted: 8 November 2021 / Published: 10 November 2021


Background: Vasculitides are specific inflammations of the blood vessel wall that can take place in any organ system of the human body. They may occur as a primary process (primary systemic vasculitides, PSV) or may be secondary to another underlying disease. In general, in association with the specific type of vasculitis, affected vessels vary in size, type, and location. In the following scoping review, we present clinical characteristics and manifestations of PSV with reference to the genitourinary system. Materials and methods: A non-systematic search of the relevant literature was conducted using three electronic databases (PubMed, Embase, and Web of Science) up to 29 October 2021. Results: Urogenital manifestations of PSV are infrequent, with the most commonly reported findings as prostatic or testicular involvements. However, almost all other organs of the genitourinary system can be affected. Conclusions: Because of the clinical heterogeneity and non-specific symptoms, the proper diagnosis of PSV is often delayed and constricted. Fast identification of urological manifestations of vasculitides is essential in implementing appropriate therapy and avoiding unnecessary, harmful, and invasive surgery.

1. Introduction

Vasculitides are specific inflammations of the blood vessel wall that can take place in any organ system of the human body. They may occur as a primary process (primary systemic vasculitides, PSV) or may be secondary to another underlying disease. The pathogenesis of PSV is poorly understood. Three of the most common mechanisms of vascular damage are immune complexes, anti-neutrophil cytoplasmic antibodies (ANCA), and cell-mediated T-lymphocyte response [1]. In association with the specific type of PSV, affected vessels vary in size, type, and location. The most commonly used nomenclature system, including the names and definitions for most forms of vasculitides, was developed by the international Chapel Hill Consensus Conference (CHCC) in 1994 and was reviewed in 2012 [2,3].
Because of the clinical heterogeneity and non-specific symptoms, the proper diagnosis of PSV is often delayed and constricted. The presence of the PSV may be mimicked by a vast number of other diseases, such as infections or neoplasms [4]. Hence, differential diagnosis requires careful assessment of all available clinical, laboratory, radiologic, and pathologic examinations (Figure 1) [5,6].
In the initial treatment of most types of PSV, glucocorticoids remain the basis, followed by the second line immunosuppressive drugs and biological agents [4]. Endovascular procedures, such as balloon angioplasty and stents or graft placement, constitute the main forms of surgical treatment. The detailed review of all available forms of PSV treatment exceeds the scope of this review, and it was not performed.
To date, a single review article regarding urological manifestations of PSV was published in 2015 [7]. Therefore, we decided to perform an updated review including recently published data. We aimed to comprehensively present clinical characteristics and manifestations of PSV with reference to urinary system involvements.

2. Evidence Acquisition

A non-systematic search of the relevant literature was conducted using three electronic databases (PubMed, Embase, and Web of Science) up to 29 October 2021. The combination of key words used for search strategy included: (“Takayasu arteritis” OR “Giant cell arteritis” OR “Polyarteritis nodosa” OR “Kawasaki disease” OR “Granulomatosis with polyangiitis” OR “Microscopic polyangiitis” OR “Eosinophilic granulomatosis with polyangiitis” OR “Immunoglobulin A vasculitis” OR “Anti-GBM disease” OR “cryoglobulinaemic vasculitis” OR “Hypocomplementaemic urticarial Vasculitis” OR “Behçet’s disease”) AND (“urinary system” OR “genitourinary system” OR “urology” OR “kidney” OR “ureter” OR “bladder” OR “prostate” OR “urethra” OR “testicle” OR “penis”). Autoalerts in Medline were also run, as well as reference lists of original and review articles for further eligible data. Only publications with abstracts written in English were considered, and evidence was limited to human data. The vast majority of analyzed articles were single case presentations or case series studies. The flow diagram of the study selection process is presented in Figure 2.

3. Evidence Synthesis

In Table 1, we summarize the main clinical symptoms of particular PSV and their possible urological manifestations. The types of PSV involving the specific parts of the urinary system are presented in Figure 3.

3.1. Large Vessel Vasculitides

3.1.1. Takayasu Arteritis (TA)

Jghaimi et al. presented a case report of a patient with suspected retroperitoneal fibrosis (RPF) and obstructive nephropathy requiring placement of double-J catheters. The diagnosis of TA was confirmed three years later when the patient presented with right upper extremity dysesthesia [8]. Aside from other cases of TA concomitant to RPF causing obstructive nephropathy, no more specific urological manifestations of TA have been reported in the literature [9].

3.1.2. Giant Cell Arteritis (GCA)

Urological manifestations of GCA seem to be extremely rare. Epididymal involvement has been reported in a 66-year-old male with a 3-month history of generalized fatigue and right-sided epididymal tenderness. Epididymal biopsy demonstrated chronic inflammatory cell infiltration and the presence of “giant cells”. The patient subsequently underwent a temporal artery biopsy, which confirmed the diagnosis of GCA [10]. Testicular involvement has been reported in a 76-year-old male with weight loss, malaise, and right testicular swelling, suspected of malignant process on ultrasonography (USG). The patient underwent radical orchidectomy, and GCA was confirmed in histopathological assessment [11]. In the existing literature, the association between GCA as a paraneoplastic condition and the development of prostate cancer (PCa) was also hypothesized [12].

3.2. Medium Vessel Vasculitides

3.2.1. Polyarteritis Nodosa (PAN)

Testicular involvement is the most characteristic urological manifestation of PAN. It is reported in 38–86% of patients based on autopsy studies, but only 2–18% of patients are symptomatic [13]. Clinically, the testicular involvement is usually characterized by pain, swelling, or erythema. Orchitis is predominantly unilateral and concomitant with systemic disease, whereas bilateral disease is extremely scarce [14]. Isolated testicular involvement, as the initial site of PAN, is rare, with only 39 cases presented in the literature up to date [15]. A heterogeneous clinical course of testicular involvement in PAN often leads to a misdiagnosis. Several authors have reported testicular masses suspicious for malignant tumors that have proven to be PAN [16,17]. In these cases, radical orchidectomies were performed, and subsequent pathological examinations revealed the presence of histological features consistent with a diagnosis of PAN. Clinical symptoms of testicular involvement in PAN can also mimic a testicular torsion [18]. In isolated testicular vasculitis in PAN, orchiectomy is considered the main therapeutic approach, with a low risk of developing systemic PAN requiring pharmacotherapy after surgery [17].
There is a single case report of a 54-year-old man with PAN affecting both the bladder and testis in the setting of cryptorchidism, without any signs of systemic disease. The patient presented a several-month history of urinary retention and intermittent gross hematuria. Cystoscopy revealed a superficial-appearing mass at the dome of his bladder. A radical right orchiectomy and transurethral resection of the bladder tumor (TURB) were performed. Histopathological examination revealed the presence of PAN vasculitis in both urinary bladder and undescended testis [15].
Renal involvement in PAN comprises tissue infarction or hematoma, typically produced from the rupture of renal microaneurysms. Kidney infarcts might be clinically silent or manifest as hematuria or proteinuria [19]. Patients may rarely be complicated by aneurismal rupture leading to subcapsular and perirenal hematomas [20,21]. Spontaneous retroperitoneal hemorrhage (also known as Wunderlich syndrome, WS) is a potentially life-threatening entity, scarcely reported in the literature [22,23]. It is classically characterized by acute flank pain, abdominal tenderness, and signs of massive internal bleeding. Aneurysms can develop due to segmental necrosis, which correlates with the severity of the illness and may cause the development of thrombosis, ruptures, and massive hemorrhage [24]. In most cases, an urgent nephrectomy is a life-saving option, but in selected cases, WS can be treated conservatively [22]. Therapeutic arterial embolization could be an alternative to surgery in patients with hemorrhage from a ruptured aneurysm, especially those in critical condition [25].
Another single-reported, rare urological manifestations of PAN include ulcerative necrosis of the glans penis and scrotum, imprints on the ureteral wall, nodular appearance of the ureter, and spontaneous ureteral rupture (SUP) [26,27,28]. In the majority of these cases, resolution of the stricture could be achieved with systemic therapy for PAN, but surgical intervention such as resection of the stenosed ureteric segment or necrotic tissue might become necessary.

3.2.2. Kawasaki Disease (KD)

There are very scarce reports of KD affecting the urinary system. Sterile pyuria is the most common abnormal finding, and some patients are misdiagnosed as having acute pyelonephritis. Sterile pyuria in KD is thought to be due to urethritis caused by a non-specific vasculitis of the urethra [29]. Kidney involvement also includes prerenal acute kidney injury (AKI), renal AKI caused by tubulointerstitial nephritis, hemolytic-uremic syndrome (HUS), immune-complex mediated nephropathy, or renal AKI associated with Kawasaki Disease Shock Syndrome (KDSS) [30]. The formation of renal artery pseudoaneurysms is an extremely rare complication of KD with an estimated 0.8% incidence rate [31].
There is a case report of a 13-year-old girl with a past medical history significant for KD and right ovarian torsion presented to the emergency department. In the physical examination, patient revealed a soft, non-tender abdomen and improvement of pain with right flank pressure. Urinalysis was positive for microhematuria, and subsequently performed computed tomography (CT) revealed right inferior pole intraparenchymal hemorrhagic mass, concerning for renal aneurysm. The patient underwent renal arteriography, which showed a 2 cm pseudoaneurysm. After confirmation of the diagnosis, embolization was performed with the good clinical outcome with preserved renal function [32]. Another urological manifestation of KD could be hydrocele testis, as described by Jibiki et al. [33].

3.3. Small Vessel Vasculitides

3.3.1. ANCA-associated Vasculitides

Granulomatosis with Polyangiitis (GPA)

Urogenital involvement in GPA is observed in approximately 1–10% of patients [34]. Prostatitis is reported in about 12–37% of patients with urogenital involvement of GPA. GPA can involve the prostate gland causing acute obstruction with the potential to recur rapidly after surgical treatment [35]. Testicular vasculitis is observed in up to 36% of patients [34]. Scrotal hyperemia, necrotic ulcers, inflammatory masses, infarction, and necrosis have also been reported [36,37]. Testicular involvement in GPA is rather concomitant with a systemic disease, although limited disease has also been reported in the literature [38]. Epididymitis as the initial manifestation of GPA was described by several authors [36,39].
Bladder involvement is another possible urological manifestation of GPA. Patients typically present with urgency and dysuria, whereas urinary incontinence and obstructive signs leading to ureter dilatation and hydronephrosis are scarcely reported [40,41]. Cystoscopy usually reveals a diffusely thickened bladder with ulcerations and fibrosis, while CT images may show wall thickening or polyps. Some patients present micro- or macrohematuria. Vesicovaginal fistula is one of the rarest manifestations of GPA [42].
Ureteral stenosis due to retroperitoneal inflammation or segmental thickening of surrounding vessels can also be associated with GPA [43]. However, it is a rare manifestation as only 11 cases have been reported in the literature to date [44]. Anuria and acute renal failure may develop in patients with bilateral stenosis [45,46].
Ulcerations of the penis have been reported in a few cases. Ulcers are usually painless, recurrent, and sometimes accompanied by local edema and regional lymphadenopathy, simulating a neoplasm. There are also case reports describing aggressive necrotizing urethritis in both male and female elderly patients. This form of destructive urethritis may mimic invasive urethral carcinoma [47,48,49].
Renal granulomatous pseudotumors, which are fibro-inflammatory masses, could be present in GPA, mimicking kidney cancer. They are usually asymptomatic and discovered incidentally on imaging studies [50].
Sometimes surgical intervention may become necessary in patients with GPA. Placing ureteral catheters as a temporary measure relieves obstruction symptoms in ureteral stenosis. In the case of urethral stricture, dilation may be required. Some patients undergo surgical procedures (orchiectomy, prostatectomy, and nephrectomy) as part of the diagnostic protocol for suspected malignant neoplasms [36].

Microscopic Polyangiitis (MPA)

Renal involvement, characterized by rapidly progressive glomerulonephritis (RPGN), is the major clinical feature of MPA with the occurrence of 80–100%. Renal manifestations can range from asymptomatic urinary sediment to end-stage renal disease requiring dialysis. Consistent with glomerulonephritis, the most common clinical symptoms of renal involvement in MPA are proteinuria, microscopic hematuria, and urinary granular or red blood cell casts [51]. Lower urogenital tract involvement in MPA is virtually not reported in the literature, except for two isolated case reports of prostatitis [52,53].

Eosinophilic Granulomatosis with Polyangiitis (EGPA)

There is a single case report describing urinary bladder involvement in association with EGPA. A 76-year-old male with a medical history of seasonal asthma, symptoms of sensory polyneuropathy in both feet and calves, cutaneous lesions on his arms and legs consistent with leukocytoclastic vasculitis, and chronic diarrhea due to ileocecal resection underwent radical cystectomy in view of high-grade cancer and severe bladder symptoms. Histopathological examination after cystectomy revealed an urothelial carcinoma, as well as intense tissue eosinophilia besides the tumor. A review of the patient’s complete medical history and the available pathology samples led to the diagnosis of EGPA [54].
Famokunwa et al. presented a case 55-year-old woman with a vesicovaginal fistula as a manifestation of EGPA. An attempt at surgical closure of the fistula failed, and a flare of the EGPA subsequent to surgical intervention resulted in rapid deterioration of her condition with acute renal failure and sepsis. Administration of methylprednisolone resulted in improvement in her pain and normalization of CRP, allowing sufficient conditions in which an ileal conduit diversion was possible [55].
Prostatic involvement is also reported in EGPA. In one case, a 74-year-old male, who had previously been treated for asthma, underwent transurethral resection of the prostate. Post-operatively he developed pyrexia and eosinophilia. The biopsy specimens showed eosinophilic prostatitis in keeping with EGPA. The patient’s symptoms responded to oral prednisolone [56]. In the second case, a 60-year-old man presented with poor urinary flow, hesitancy, and nocturia underwent TURP. Histology showed fibromuscular hyperplasia and florid eosinophilic prostatitis. Two weeks after discharge, he was admitted as an emergency with a rash affecting both ankles and legs. The clinical and laboratory findings suggested EGPA with cutaneous, prostatic, and possibly renal involvement [57].
Urological manifestation of EGPA may also concern ureteric obstruction secondary to calcification and stenosis [58,59], bilateral ureteral stenosis with anuria [60], ulceration of the mid-penile urethra [61], and funiculitis [62], but only a few case reports are available in the literature.

3.3.2. Small Vessels Vasculitides Associated with Immune Complex Deposition

Immunoglobulin A Vasculitis (IgAV)

Involvement of urinary tract in IgAV was reported in several cases, including scrotum, testicle, ureter, bladder, prostate, and penis. Common testicular manifestations of IgAV include acute scrotum, epididymitis, orchitis, and spermatic cord complications [63]. It may require assessment by an experienced pediatric surgeon to exclude a testicular torsion, which requires surgical emergency instead of conservative management. Orchitis is usually gradual in nature with associated nausea and vomiting, whereas scrotal involvement due to IgAV presents with instantaneous pain, typically without nausea or vomiting [64]. Hematomas and edema of the spermatic cord are rare urological complications of IgAV and they could be also confused with testicular torsion and acute scrotum. Some patients with spermatic cord involvement suffer from thrombosis of the spermatic veins; however, it is not typically seen in children [65]. Penile manifestations of IgAV include thrombosis, priapism, and purpuric lesions on the penis. Such lesions may appear before or after the onset of IgAV [66]. Ureteral involvement often results in ureter obstruction. Obstruction is either unilateral or bilateral and may be partial or complete depending on the severity of the case [67]. Residual stenotic lesions and subsequent urinary tract obstruction frequently require surgical intervention [68]. Bilateral and unilateral ureteritis are other complications reported in IgAV, and they appear about 1–2 months after the onset of the disease [69]. In some cases, ureteritis is accompanied by nephritis, which results in delayed diagnosis and an increased risk of complications [70].
IgAV could also affect the urinary bladder. Hirayama et al. described an 83-year-old man who developed IgAV in the course of Bacillus Calmette–Guerin (BCG) intravesical therapy. Following the BCG maintenance, purpura appeared on the lower region of the patient’s legs [71]. Ishigaki et al. described a 70-year-old male with bladder cancer diagnosed with IgAV following neoadjuvant chemotherapy and a radical cystectomy. Twenty-three days after radical cystectomy, the patient presented with purpura, and the diagnosis of IgAV was made based on a skin biopsy [72].
In adults, IgAV has been linked to PCa. The relationship between the development of IgAV and PCa remains unknown, but it is postulated that tumor antigens or irregular IgA production may be contributing factors [73].

Other Small Vessels Vasculitides Associated with Immune Complex Deposition

Other small vessel vasculitides associated with immune complex deposition are anti-glomerular basement membrane antibody (Anti-GBM disease, former Goodpasture’s Syndrome), cryoglobulinemic vasculitis, and Hypocomplementemic urticarial Vasculitis (HUV, anti-C1q vasculitis). Urinary system involvement in these diseases is reported exceptionally. No lower urinary tract manifestations of the anti-GBM disease have been presented in the literature. Glomerulonephritis with non-visible hematuria appears to be the only reported urological manifestation of cryoglobulinemic vasculitis [74]. It is estimated that approximately 50% of all HUV patients will have renal involvement [75].

3.4. Variable Vessels Vasculitides

Behçet’s Disease (BD)

The most specific urological manifestations for BD are genital ulcerations, occurring in approximately 75% of patients with BD. Genital ulcers are most commonly found on the scrotum in men and the vulva in women. The ulcers are similar in appearance to the oral aphthae, and they are usually painful. An unusual reported localization of genital ulcers in BD is external urethral meatus [76]. The recurrence rate is typically less frequent compared to oral ulcerations. However, genital lesions are usually deeper and last longer than oral ulcers [76]. Due to the clinical heterogeneity of BD and the unpredictable disease course, the systemic treatment is tailored to the severity of symptoms and organ involvement. For mild oral and genital ulcerations, the current recommendation as first-line therapy is application of topical agents [76].
Other urological involvements are encountered scarcely, usually in the form of epididymitis [77]. There is a single case report of bilateral epididymitis in a 24-year-old man with ulcerous lesions, erythema nodosum, folliculitis-like exanthema, and multiple oral aphthae, eventually diagnosed as BD [78].
Another reported urological manifestation of BD is deep dorsal penile vein thrombosis (DDPVT). It requires an early etiological and symptomatic approach to preserve erectile function and prevent recurrences. Beddouche et al. presented a case of dorsal penile vein thrombosis revealed by spontaneous priapism that didn’t resolve adequately. After the management of priapism and DDPVT, the etiological investigation revealed BD. The patient underwent etiological treatment with good clinical evolution and preservation of erectile function [79].
The urethrovaginal fistula formation may occur during the course of the BD. The pathogenesis of fistula is related to inflammation, and finally, necrosis caused by severe vasculitis. A few case reports are available in the literature [80]. Surgical treatment may be performed for repairing the urethrovaginal fistula, and in the mid-term, it may be successful. Long-term follow-up is necessary because of the high recurrence rate.
The incidence of bladder involvement in BD is considered to be 0.1% [81]. Direct involvement of the bladder is possible in the form of ulceration, nodules, or recurrent cystitis. Storage symptoms could also be observed in patients with BD as a result of neuro-Behcet’s disease, direct bladder wall infiltration, or their combination [82]. Urge incontinence, emptying symptoms, and urinary retention may also occur. Sphincter function can be normal. However, detrusor sphincter dyssynergia or sphincter deficiency could also be observed [82]. Gross hematuria is very rare. Treatment of bladder dysfunction is individualized for each patient according to their urodynamic and imaging findings. Emptying failure is usually managed by clean intermittent catheterization while storage problems have been treated by anticholinergics. However, augmentation cystoplasty becomes mandatory occasionally.

4. Conclusions

Urological manifestations of PSV are infrequent. However, almost all organs of the genitourinary system can be affected. In general, the presence of vasculitis should be considered in patients who present with systemic or constitutional symptoms in combination with evidence of single and/or multiorgan dysfunction and especially with some key manifestations. Proper diagnosis requires careful assessment of all available clinical, laboratory, radiologic, and pathologic examinations. Fast diagnosis of PSV in patients with urological involvement is crucial in implementing appropriate therapy, and it allows to avoid unnecessary and invasive surgery in some cases.

Author Contributions

Conceptualization, Ł.N. and W.K.; methodology, Ł.N.; validation, Ł.N., W.K. and P.K.; formal analysis, B.M.; investigation, Ł.N.; resources, Ł.N. and J.C.; data curation, J.K. and J.C.; writing—original draft preparation, Ł.N. and W.K.; writing—review and editing, Ł.N. and B.M.; visualization, P.K.; supervision, T.S. All authors have read and agreed to the published version of the manuscript.


This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.


  1. Khasnis, A.; Langford, C.A. Update on vasculitis. J. Allergy Clin. Immunol. 2009, 123, 1226–1236. [Google Scholar] [CrossRef] [PubMed]
  2. Jennette, J.C.; Falk, R.J.; Andrassy, K.; Bacon, P.A.; Churg, J.; Gross, W.L.; Hagen, E.C.; Hoffman, G.S.; Hunder, G.G.; Kallenberg, C.G.; et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994, 37, 187–192. [Google Scholar] [CrossRef] [PubMed]
  3. Jennette, J.C.; Falk, R.J.; Bacon, P.A.; Basu, N.; Cid, M.C.; Ferrario, F.; Flores-Suarez, L.F.; Gross, W.L.; Guillevin, L.; Hagen, E.C.; et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013, 65, 1–11. [Google Scholar] [CrossRef] [PubMed]
  4. Elefante, E.; Bond, M.; Monti, S.; Lepri, G.; Cavallaro, E.; Felicetti, M.; Calabresi, E.; Posarelli, C.; Talarico, R.; Quartuccio, L.; et al. One year in review 2018: Systemic vasculitis. Clin. Exp. Rheumatol. 2018, 36 (Suppl. 111), 12–32. [Google Scholar] [PubMed]
  5. Bateman, H.; Rehman, A.; Valeriano-Marcet, J. Vasculitis-like Syndromes. Curr. Rheumatol. Rep. 2009, 11, 422–429. [Google Scholar] [CrossRef]
  6. Molloy, E.S.; Langford, C.A. Vasculitis mimics. Curr. Opin. Rheumatol. 2008, 20, 29–34. [Google Scholar] [CrossRef]
  7. Peracha, J. Urological manifestations and treatment of the primary systemic vasculitides. World J. Clin. Urol. 2015, 4, 5. [Google Scholar] [CrossRef]
  8. Jghaimi, F.; Kabbaj, A.; Essaadouni, L. Takayasu’s arteritis and retroperitoneal fibrosis: A case report. Rev. Med. Interne 2010, 31, e1–e3. [Google Scholar] [CrossRef]
  9. Houman, H.; Haouet, S.; Lamloum, M.; Ghorbel, I.B.; Miled, M. Retroperitoneal fibrosis associated with Takayasu arteritis. Ann. Med. Interne 1998, 149, 107–108. [Google Scholar]
  10. Arnillas, E.; de la Fuente, J.; Nunez, M.; Dominguez, F. Giant cell arteritis with epididymal involvement. Med. Clin. 2009, 132, 485. [Google Scholar] [CrossRef]
  11. Sundaram, S.; Smith, D.H. Giant cell arteritis mimicking a testicular tumour. Rheumatol. Int. 2001, 20, 215–216. [Google Scholar] [CrossRef]
  12. Figueiredo, C.; Amaral, M.; Rodrigues, É.; Silva, R.; Vilão, Ó. Paraneoplastic giant cell arteritis and prostate cancer: A case report of a not common association. Clin. Case Rep. 2021, 9, 1405–1407. [Google Scholar] [CrossRef] [PubMed]
  13. Teichman, J.M.; Mattrey, R.F.; Demby, A.M.; Schmidt, J.D. Polyarteritis nodosa presenting as acute orchitis: A case report and review of the literature. J. Urol. 1993, 149, 1139–1140. [Google Scholar] [CrossRef]
  14. Bhatia, S.; Herrera Hernandez, L.P.; Kamboj, A.K.; Rieck, K.M. Isolated Polyarteritis Nodosa Presenting as Bilateral Testicular Swelling. Am. J. Med. 2018, 131, e55–e56. [Google Scholar] [CrossRef] [PubMed]
  15. Stewart, M.; Marcotte, G.; Seidman, M.A.; Dehghan, N. Polyarteritis nodosa isolated to the testis and urinary bladder in the setting of cryptorchidism: A case report and literature review. J. Med. Case Rep. 2019, 13, 236. [Google Scholar] [CrossRef]
  16. Huisman, T.K.; Collins, W.T., Jr.; Voulgarakis, G.R. Polyarteritis nodosa masquerading as a primary testicular neoplasm: A case report and review of the literature. J. Urol. 1990, 144, 1236–1238. [Google Scholar] [CrossRef]
  17. Atis, G.; Memis, O.F.; Güngör, H.S.; Arikan, O.; Saglican, Y.; Caskurlu, T. Testicular polyarteritis nodosa mimicking testicular neoplasm. Sci. World J. 2010, 10, 1915–1918. [Google Scholar] [CrossRef]
  18. Gervaise, A.; Junca-Laplace, C.; Naulet, P.; Pernin, M.; Portron, Y.; Lapierre-Combes, M. Unilateral testicular vasculitis in polyarteritis nodosa mimicking a testicular torsion. Diagn. Interv. Imaging 2014, 95, 615–616. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Pagnoux, C.; Seror, R.; Henegar, C.; Mahr, A.; Cohen, P.; Le Guern, V.; Bienvenu, B.; Mouthon, L.; Guillevin, L. Clinical features and outcomes in 348 patients with polyarteritis nodosa: A systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum. 2010, 62, 616–626. [Google Scholar] [CrossRef] [PubMed]
  20. McKinnon, K.; Baker, K.; Ravi, R. Case of spontaneous bilateral perinephric hematomas. Int. J. Urol. Off. J. Jpn. Urol. Assoc. 2015, 22, 137–138. [Google Scholar] [CrossRef] [Green Version]
  21. Miyagawa, T.; Iwata, Y.; Oshima, M.; Ogura, H.; Sato, K.; Nakagawa, S.; Yamamura, Y.; Kitajima, S.; Toyama, T.; Hara, A.; et al. Polyarteritis nodosa with perirenal hematoma due to the rupture of a renal artery aneurysm. CEN Case Rep. 2021, 10, 244–249. [Google Scholar] [CrossRef] [PubMed]
  22. Simsek, E.; Yilmaz, H.; Teke, K.; Uslubas, A.K.; Yuksekkaya, M. Spontaneous Retroperitoneal Haematoma due to Polyarteritis Nodosa: Report of a Case and Literature Review. Case Rep. Urol. 2016, 2016, 7592563. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Venkatramani, V.; Banerji, J.S. Spontaneous perinephric hemorrhage (Wunderlich syndrome) secondary to polyarteritis nodosa: Computed tomography and angiographic findings. Indian J. Urol. 2014, 30, 452–453. [Google Scholar] [CrossRef] [PubMed]
  24. Peddi, P.; Kalavakunta, J.K.; Annakula, M.; Armstrong, J.R. An unusual complication of polyarteritis nodosa with massive retroperitoneal hemorrhage: A case report. Int. Arch. Med. 2010, 3, 31. [Google Scholar] [CrossRef] [Green Version]
  25. Hachulla, E.; Bourdon, F.; Taieb, S.; Robert, Y.; Amrouni, N.; Steckolorom, T.; Jabinet, J.L.; Hatron, P.Y.; Devulder, B. Embolization of two bleeding aneurysms with platinum coils in a patient with polyarteritis nodosa. J. Rheumatol. 1993, 20, 158–161. [Google Scholar]
  26. Karademir, K.; Senkul, T.; Atasoyu, E.; Yildirim, S.; Nalbant, S. Ulcerative necrosis of the glans penis resulting from polyarteritis nodosa. J. Clin. Rheumatol. 2005, 11, 167–169. [Google Scholar] [CrossRef] [PubMed]
  27. Bolat, D.; Zumrutbas, A.E.; Baser, A.; Tuncay, L. Spontaneous ureteral rupture in a patient with polyarteritis nodosa. Int. Urol. Nephrol. 2016, 48, 223–224. [Google Scholar] [CrossRef]
  28. Grinstein, P.; Maximiliano, L.S.; Lucas, Y.; Norberto, B. Polyarteritis nodosa with genital necrosis. Urol. Case Rep. 2020, 33, 101285. [Google Scholar] [CrossRef]
  29. Wu, C.Y.; Hsieh, K.S.; Chiou, Y.H.; Wang, R.S.; Huang, I.F.; Lee, W.Y.; Chiou, C.C. Prolonged fever and pyuria: A urinary tract infection presentation of incomplete Kawasaki disease. Acta Paediatr. 2005, 94, 375–377. [Google Scholar] [CrossRef]
  30. Watanabe, T. Kidney and urinary tract involvement in kawasaki disease. Int. J. Pediatr. 2013, 2013, 831834. [Google Scholar] [CrossRef] [Green Version]
  31. Kato, H.; Sugimura, T.; Akagi, T.; Sato, N.; Hashino, K.; Maeno, Y.; Kazue, T.; Eto, G.; Yamakawa, R. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996, 94, 1379–1385. [Google Scholar] [CrossRef] [PubMed]
  32. Chen, A.; DeBartolo, M.; Darras, F.; Ferretti, J.; Wasnick, R. Renal Artery Pseudoaneurysm in Kawasaki Disease. Urology 2016, 98, 165–166. [Google Scholar] [CrossRef] [PubMed]
  33. Jibiki, T.; Sakai, T.; Saitou, T.; Kanazawa, M.; Ide, T.; Fujita, M.; Iida, Y.; Yamazaki, S.; Ishiwada, F.; Sato, J. Acute scrotum in Kawasaki disease: Two case reports and a literature review. Pediatr. Int. 2013, 55, 771–775. [Google Scholar] [CrossRef] [PubMed]
  34. Dufour, J.F.; Le Gallou, T.; Cordier, J.F.; Aumaitre, O.; Pinede, L.; Aslangul, E.; Pagnoux, C.; Marie, I.; Puechal, X.; Decaux, O.; et al. Urogenital manifestations in Wegener granulomatosis: A study of 11 cases and review of the literature. Medicine 2012, 91, 67–74. [Google Scholar] [CrossRef] [PubMed]
  35. Neerhut, T.; Neerhut, G.; Magree, C. Rapidly recurrent prostatic obstruction due to granulomatosis with polyangiitis. Urol. Case Rep. 2021, 39, 101771. [Google Scholar] [CrossRef] [PubMed]
  36. Lee, S.S.; Tang, S.H.; Sun, G.H.; Yu, C.P.; Jin, J.S.; Chang, S.Y. Limited Wegener’s granulomatosis of the epididymis and testis. Asian J. 2006, 8, 737–739. [Google Scholar] [CrossRef]
  37. Barber, T.D.; Al-Omar, O.; Poulik, J.; McLorie, G.A. Testicular infarction in a 12-year-old boy with Wegener’s granulomatosis. Urology 2006, 67, 846.E9–846.E10. [Google Scholar] [CrossRef]
  38. Hernandez-Rodriguez, J.; Tan, C.D.; Koening, C.L.; Khasnis, A.; Rodriguez, E.R.; Hoffman, G.S. Testicular vasculitis: Findings differentiating isolated disease from systemic disease in 72 patients. Medicine 2012, 91, 75–85. [Google Scholar] [CrossRef]
  39. Miller, D.C.; Koss, M.N. Wegener granulomatosis presenting as epididymitis. Urology 2009, 73, 1225–1226. [Google Scholar] [CrossRef]
  40. Hooda, D.; Parsons, J.; Hooda, S.; Nuss, M.; Layne, R. Isolated bladder vasculitis: A rare presentation of Wegener’s granulomatosis. W Va. Med. J. 2011, 107, 24–25. [Google Scholar]
  41. Hansen, B.J.; Horby, J.; Hansen, H.J. Wegener’s granulomatosis in the bladder. Br. J. Urol. 1990, 65, 108–109. [Google Scholar] [CrossRef] [PubMed]
  42. Davenport, A.; Downey, S.E.; Goel, S.; Maciver, A.G. Wegener’s granulomatosis involving the urogenital tract. Br. J. Urol. 1996, 78, 354–357. [Google Scholar] [CrossRef] [PubMed]
  43. Šoštarič, K.; Krstić, T.L.; Slanič, A.; Caf, P. A Rare Case of Granulomatosis With Polyangiitis Presenting as Retroperitoneal Fibrosis in the Peri-Iliac Region Causing Hydronephrosis. Cureus 2021, 13, e17295. [Google Scholar] [CrossRef]
  44. Suillot, J.; Bollmann, J.; Rotman, S.; Descombes, E. Bilateral Ureteral Stenosis with Hydronephrosis as First Manifestation of Granulomatosis with Polyangiitis (Wegener’s Granulomatosis): A Case Report and Review of the Literature. Case Rep. Nephrol. 2020, 2020, 7189497. [Google Scholar] [CrossRef] [PubMed]
  45. Lillaz, J.; Bernardini, S.; Algros, M.P.; Bittard, H.; Kleinclauss, F. Wegener’s granulomatosis: A rare cause of hydronephrosis. Case Rep. Med. 2011, 2011, 814794. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Sataa, S.; Ben Rhouma, S.; Tanguour, M.; Rebai, S.; Cherif, K.; Kchir, N.; Nouira, Y.; Benrais, N.; Horchani, A. Ureteral stenosis due to Wegener’s granulomatosis. Tunis Med. 2011, 89, 725–726. [Google Scholar] [PubMed]
  47. Anderson, P.T.; Gottheil, S.; Gabril, M.; Barra, L.; Power, N. Acute urinary retention secondary to urethral involvement of granulomatosis with polyangiitis. Can. Urol. Assoc. J. 2017, 11, E38–E40. [Google Scholar] [CrossRef] [Green Version]
  48. Al Rajabi, W.; Venturini, M.; Sala, R.; Calzavara-Pinton, P. Wegener’s granulomatosis of the penis: Genital presentation of systemic disease. Dermatology 2006, 212, 370–372. [Google Scholar] [CrossRef]
  49. Bories, N.; Becuwe, C.; Marcilly, M.C.; Wolf, F.; Balme, B.; Thomas, L. Glans penis ulceration revealing Wegener’s granulomatosis. Dermatology 2007, 214, 187–189. [Google Scholar] [CrossRef]
  50. Ward, A.; Konya, C.; Mark, E.J.; Rosen, S. Granulomatosis with polyangiitis presenting as a renal tumor. Am. J. Surg. Pathol. 2014, 38, 1444–1448. [Google Scholar] [CrossRef]
  51. Greco, A.; De Virgilio, A.; Rizzo, M.I.; Gallo, A.; Magliulo, G.; Fusconi, M.; Ruoppolo, G.; Tombolini, M.; Turchetta, R.; de Vincentiis, M. Microscopic polyangiitis: Advances in diagnostic and therapeutic approaches. Autoimmun. Rev. 2015, 14, 837–844. [Google Scholar] [CrossRef] [PubMed]
  52. Ashikaga, E.; Iyoda, M.; Suzuki, H.; Nagai, H.; Shibata, T.; Akizawa, T. Case of microscopic polyangiitis presenting initially as prostatic vasculitis. Nihon Jinzo Gakkai Shi 2009, 51, 1075–1079. [Google Scholar] [PubMed]
  53. Lamarche, J.A.; Peguero, A.M.; Rosario, J.O.; Patel, A.; Courville, C. Anti-MPO small-vessel vasculitis causing prostatis and nephritis. Clin. Exp. Nephrol. 2007, 11, 180–183. [Google Scholar] [CrossRef] [PubMed]
  54. Heers, H.; Ramaswamy, A.; Hofmann, R. A Case of Churg-Strauss Syndrome (Eosinophilic Granulomatosis with Polyangiitis) of the Urinary Bladder. Urology 2017, 108, 7–10. [Google Scholar] [CrossRef] [PubMed]
  55. Famokunwa, B.; Ockrim, J.; Manson, J.J. Eosinophilic granulomatosis with polyangiitis presenting with a vesicovaginal fistula. Rheumatology 2017, 56, 1080. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Kiyokawa, H.; Koyama, M.; Kato, H. Churg-Strauss syndrome presenting with eosinophilic prostatitis. Int. J. Urol. Off. J. Jpn. Urol. Assoc. 2006, 13, 838–840. [Google Scholar] [CrossRef]
  57. Raza, A.; Ong, E.K.; Palmer, T.; Bramwell, S.P. Churg-Strauss syndrome and eosinophilic prostatitis. BJU Int. 2003, 92 (Suppl. 3), e24–e25. [Google Scholar] [CrossRef]
  58. Symes, A.; Kalsi, V.; Rickards, D.; Allen, C.; Choong, S.; Philp, T. Dystrophic ureteral calcification associated with Churg-Strauss vasculitis. Urology 2004, 64, 1231. [Google Scholar] [CrossRef]
  59. Yagihashi, Y.; Toyosato, T.; Shimabukuro, S.; Kato, H. Bilateral calcified ureteral stricure requiring urinary reconstruction in eosinophilic granulomatosis with polyangitis: A case report. Nihon Hinyokika Gakkai Zasshi 2020, 111, 140–144. [Google Scholar] [CrossRef]
  60. Cortellini, P.; Manganelli, P.; Poletti, F.; Sacchini, P.; Ambanelli, U.; Bezzi, E. Ureteral involvement in the Churg-Strauss syndrome: A case report. J. Urol. 1988, 140, 1016–1018. [Google Scholar] [CrossRef]
  61. Walsh, I.; Loughridge, W.G.; Keane, P.F. Eosinophilic vasculitis (Churg-Strauss syndrome) involving the urethra. Br. J. Urol. 1994, 74, 255–256. [Google Scholar] [CrossRef]
  62. Fukui, S.; Iwamoto, N.; Mochizuki, Y.; Nakajima, H.; Abe, K.; Kawakami, A. Eosinophilic granulomatosis with polyangiitis along with funiculitis and myelitis. Int. J. Rheum. Dis. 2017, 20, 2203–2205. [Google Scholar] [CrossRef]
  63. Ha, T.S.; Lee, J.S. Scrotal involvement in childhood Henoch-Schonlein purpura. Acta Paediatr. 2007, 96, 552–555. [Google Scholar] [CrossRef]
  64. Gunes, M.; Kaya, C.; Koca, O.; Keles, M.O.; Karaman, M.I. Acute scrotum in Henoch-Schonlein purpura: Fact or fiction? Turk. J. Pediatr. 2012, 54, 194–197. [Google Scholar]
  65. Diana, A.; Gaze, H.; Laubscher, B.; De Meuron, G.; Tschantz, P. A case of pediatric Henoch-Schonlein purpura and thrombosis of spermatic veins. J. Pediatr. Surg. 2000, 35, 1843. [Google Scholar] [CrossRef]
  66. Sari, I.; Akar, S.; Secil, M.; Birlik, M.; Kefi, A.; Onen, F.; Celebi, I.; Akkoc, N. Thrombosis and priapism in a patient with Henoch-Schonlein purpura. Rheumatol. Int. 2005, 25, 472–474. [Google Scholar] [CrossRef]
  67. Bruce, R.G.; Bishof, N.A.; Jackson, E.C.; Skinker, D.M.; McRoberts, J.W. Bilateral ureteral obstruction associated with Henoch-Schoenlein purpura. Pediatr. Nephrol. 1997, 11, 347–349. [Google Scholar] [CrossRef] [PubMed]
  68. Powell, J.M.; Ware, H.; Williams, G. Recurrent ureteric obstruction in association with Henoch-Schonlein purpura. Postgrad. Med. J. 1987, 63, 699–701. [Google Scholar] [CrossRef] [Green Version]
  69. Corbett, S.T.; Lennington, J.N.; Chua, A.N.; Gonzales, E.T., Jr. Stenosing ureteritis in a 7-year-old boy with Henoch-Schonlein purpura nephritis: A case report and review of the literature. J. Pediatr. Urol. 2010, 6, 538–542. [Google Scholar] [CrossRef]
  70. Siomou, E.; Serbis, A.; Salakos, C.; Papadopoulou, F.; Stefanidis, C.J.; Siamopoulou, A. Masked severe stenosing ureteritis: A rare complication of Henoch-Schonlein purpura. Pediatr. Nephrol. 2008, 23, 821–825. [Google Scholar] [CrossRef]
  71. Hirayama, T.; Matsumoto, K.; Tsuboi, T.; Fujita, T.; Satoh, T.; Iwamura, M.; Ao, T.; Baba, S. Anaphylactoid purpura after intravesical therapy using bacillus Calmette-Guerin for superficial bladder cancer. Hinyokika Kiyo 2008, 54, 127–129. [Google Scholar]
  72. Ishigaki, H.; Itou, H.; Takeshima, T.; Kawai, M.; Hirai, K.; Shirai, A.; Horita, A.; Saitou, I. Henoch-Schonlein purpura developed after radical cystectomy. Hinyokika Kiyo 2013, 59, 663–667. [Google Scholar] [PubMed]
  73. Sobieszczanska, M.; Tubek, S.; Poplicha, D.; Grabelus, A.; Pawelczak, J. Henoch-Schonlein purpura (HSP) and high-dose immunoglobulin treatment in patient with familiar prostatic adenocarcinoma. Hum. Vaccines Immunother. 2014, 10, 358–359. [Google Scholar] [CrossRef] [PubMed]
  74. Braun, G.S.; Horster, S.; Wagner, K.S.; Ihrler, S.; Schmid, H. Cryoglobulinaemic vasculitis: Classification and clinical and therapeutic aspects. Postgrad. Med. J. 2007, 83, 87–94. [Google Scholar] [CrossRef] [PubMed]
  75. Buck, A.; Christensen, J.; McCarty, M. Hypocomplementemic urticarial vasculitis syndrome: A case report and literature review. J. Clin. Aesthet. Derm. 2012, 5, 36–46. [Google Scholar]
  76. Turan, Ç.; Karabulut, İ. An unusual localisation of genital ulcer in Behçet’s disease: External urethral meatus. Int. J. Clin. Pract. 2021, 75, e14504. [Google Scholar] [CrossRef]
  77. Kirkali, Z.; Yigitbasi, O.; Sasmaz, R. Urological aspects of Behcet’s disease. Br. J. Urol. 1991, 67, 638–639. [Google Scholar] [CrossRef]
  78. Horii, S.; Takada, S.; Kinjo, T.; Nonomura, D.; Yamamoto, Y.; Yoneda, S.; Nomura, H.; Tei, N.; Matsumiya, K.; Shiroyama, Y. Case of Behcet’s disease diagnosed by bilateral epididymitis. Hinyokika Kiyo 2014, 60, 593–596. [Google Scholar]
  79. Beddouche, A.; Ouaziz, H.; Zougaghi, S.; Alaoui, A.; Dergamoun, H.; El Sayegh, H.; Iken, A.; Benslimane, L.; Nouini, Y. Deep dorsal penile vein thrombosis revealing Behcet’s disease. Pan Afr. Med. J. 2016, 24, 17. [Google Scholar] [CrossRef]
  80. Akin, Y.; Yucel, S.; Baykara, M. An extremely rare manifestation of Behcet’s disease: Urethrovaginal fistula. Int. Urol. Nephrol. 2014, 46, 359–361. [Google Scholar] [CrossRef]
  81. Cetinel, B.; Akpinar, H.; Tufek, I.; Uygun, N.; Solok, V.; Yazici, H. Bladder involvement in Behcet’s syndrome. J. Urol. 1999, 161, 52–56. [Google Scholar] [CrossRef]
  82. Alizadeh, F.; Khorrami, M.H.; Izadpanahi, M.H.; Nouri-Mahdavi, K.; Mohammadi Sichani, M. Bladder involvement in Behcet’s disease. Urol. J. 2012, 9, 347–350. [Google Scholar] [PubMed]
Figure 1. Basic methods used in diagnostic evaluation of primary systemic vasculitides.
Figure 1. Basic methods used in diagnostic evaluation of primary systemic vasculitides.
Uro 01 00023 g001
Figure 2. Flow diagram of study selection process.
Figure 2. Flow diagram of study selection process.
Uro 01 00023 g002
Figure 3. The types of primary systemic vasculitides involving the specific parts of the urinary system. TA—Takayasu arteritis; GCA—giant cell arteritis; PAN—polyarteritis nodosa; KD—Kawasaki disease; GPA—granulomatosis with polyangiitis; EGPA—eosinophilic granulomatosis with polyangiitis; IgAV—IgA vasculitis; BD—Bechet’s disease; *—involvement other than glomeluronephritis.
Figure 3. The types of primary systemic vasculitides involving the specific parts of the urinary system. TA—Takayasu arteritis; GCA—giant cell arteritis; PAN—polyarteritis nodosa; KD—Kawasaki disease; GPA—granulomatosis with polyangiitis; EGPA—eosinophilic granulomatosis with polyangiitis; IgAV—IgA vasculitis; BD—Bechet’s disease; *—involvement other than glomeluronephritis.
Uro 01 00023 g003
Table 1. Main clinical symptoms of particular primary systemic vasculitides and their possible urological manifestations.
Table 1. Main clinical symptoms of particular primary systemic vasculitides and their possible urological manifestations.
TypeMain SymptomsUrological Manifestations
Large Vessel Vasculitis
Takayasu arteritis (TA)Arthralgia, myalgia, carotidynia, absent or weak peripheral pulse, limb claudication, arterial bruit, discrepant blood pressure between arms, hypertension, angina, gastrointestinal symptoms (abdominal pain, diarrhea, gastrointestinal hemorrhage) skin lesions (erythema nodosum, pyoderma gangrenosum), respiratory symptoms (chest pain, dyspnea, hemoptysis, pulmonary hypertension), neurologic symptoms (light headedness, vertigo, syncope, orthostasis, headaches, convulsions, and strokes), visual impairmentObstructive nephropathy
Giant cell arteritis (GCA)Jaw claudication, ocular symptoms (transient visual loss, permanent vision loss, diplopia, Charles Bonnet syndrome), musculoskeletal symptoms (proximal polyarthralgias and myalgias, peripheral synovitis, distal extremity swelling with pitting edema), large vessel involvement (aneurysms and dissections of the aorta, stenosis, occlusion, and ectasia of large arteries), strokesEpididymitis, orchitis, testicular masses
Medium Vessel Vasculitis
Polyarteritis nodosa (PAN)Skin lesions (tender erythematous nodules, purpura, livedo reticularis, ulcers, bullous or vesicular eruption), neurologic symptoms (mononeuropathy multiplexor asymmetric polyneuropathy affecting, e.g., radial, ulnar, peroneal nerves), gastrointestinal symptoms (abdominal pain, nausea, vomiting, melena, bloody or non-bloody diarrhea, life-threatening gastrointestinal bleeding), coronary artery disease (myocardial ischemia, heart failure, cardiomyopathy), myalgia and muscle weakness, ocular symptoms (ischemic retinopathy with hemorrhages, retinal detachment, ischemic optic neuropathy), glomerulonephritisOrchitis, scrotal necrosis, bladder and testicular masses, ureteric stricture, spontaneous ureteric rupture, renal artery aneurysms, perirenal hematomas, spontaneous retroperitoneal hemorrhage
Kawasaki disease (KD)Conjunctivitis, mucositis, skin lesions (rash, perineal erythema, redness or crust formation at the site of Bacille Calmette–Guérin inoculation), extremity changes (indurated edema of the dorsum of their hands and feet, diffuse erythema of their palms and soles), arthritis, lymphadenopathy (cervical lymphadenopathy), cardiovascular involvement (coronary arteries inflammation, formation of microaneurysms, myocarditis, pericarditis, valvulitis)Sterile pyuria, hydrocele testis
Small Vessel Vasculitis
Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis
Microscopic polyangiitis (MPA)Elevated purpura, alveolar hemorrhage, glomerulonephritisProstatitis
Granulomatosis with polyangiitis (GPA)Upper airways, eye and ear disease (conductive hearing loss, sensorineural hearing loss, strawberry gingivitis, underlying bone destruction with loosening of teeth, non-specific ulcerations throughout the lining of the mouth and nasal septum), renal involvement (rapidly progressive glomerulonephritis), subglottal stenosis, lower respiratory tract involvement (pulmonary nodules, cavitary lesions, bleeding in the lungs, bronchial stenosis), arthritis, skin lesions (subcutaneous nodule on the elbow, purpura), neurologic symptoms: (sensory neuropathy, mononeuritis multiplex)Prostatitis, epididymitis, orchitis, ureteric stricture, penile ulceration, necrotizing urethritis, large renal and bladder granulomas, vesicovaginal fistula
Eosinophilic granulomatosis with polyangiitis (EGPA)Respiratory symptoms (asthma, allergic rhinitis, nasal polyps, pulmonary bleeding), neurologic symptoms (mononeuropathy multiplex, symmetrical polyneuropathy), renal involvement (glomerulonephritis, hypertension), cardiovascular involvement (myocarditis, pericarditis), skin lesions (elevated purpura, subcutaneous nodules, livedo reticularis), gastrointestinal symptoms (eosinophilic gastroenteritis, diarrhea, gastrointestinal bleeding, colitis)Prostatitis, cystitis, ureteric stricture, vesicovaginal fistula
Immune complex small vessel vasculitides
IgA vasculitis (IgAV)Skin lesions (symmetrical erythematosus petechial or purpuric rash that almost exclusively starts on the lower limbs and buttocks), arthritis, gastrointestinal symptoms (nausea, vomiting, colicky abdominal pain, transient paralytic ileus, gastrointestinal hemorrhage, bowel ischemia and necrosis, intussusception, bowel perforation), glomerulonephritisEpididymitis, orchitis, ureteric stricture, cystitis, priapism, spermatic vein thrombosis
Variable Vessel Vasculitis
Bechet’s disease (BD)Oral ulcerations, skin lesions (acneiform lesions, papulo-vesiculo-pustular eruptions, pseudofolliculitis, nodules, erythema, palpable purpura), ocular disease (uveitis, secondary cataracta, glaucoma, macular edema), neurologic symptoms, arterial disease (hemorrhage, stenosis, aneurysm formation), venous thrombosis, cardiac disease, gastrointestinal symptoms (abdominal pain, diarrhea, gastrointestinal ulcerations, bleeding)Genital ulceration, epididymitis, sterile urethritis, bladder wall ulceration, cystitis, vesicovaginal fistula, urethrovaginal fistula, priapism
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Nowak, Ł.; Krajewski, W.; Krajewska, J.; Chorbińska, J.; Kiełb, P.; Małkiewicz, B.; Szydełko, T. Urological Manifestations of the Systemic Vasculitides—A Scoping Review. Uro 2021, 1, 209-221.

AMA Style

Nowak Ł, Krajewski W, Krajewska J, Chorbińska J, Kiełb P, Małkiewicz B, Szydełko T. Urological Manifestations of the Systemic Vasculitides—A Scoping Review. Uro. 2021; 1(4):209-221.

Chicago/Turabian Style

Nowak, Łukasz, Wojciech Krajewski, Joanna Krajewska, Joanna Chorbińska, Paweł Kiełb, Bartosz Małkiewicz, and Tomasz Szydełko. 2021. "Urological Manifestations of the Systemic Vasculitides—A Scoping Review" Uro 1, no. 4: 209-221.

Article Metrics

Back to TopTop